LianBio sells NBTXR3 rights in Asia to Janssen for $25M upfront plus potential $5M milestone

LianBio

Asset Purchase Agreement with Janssen (Johnson & Johnson) executed Dec 22, 2023.
LianBio receives $25 million one-time payment at closing.
Eligible for $5 million milestone if annual net sales in PRC exceed $20 million.
Transition activities to be completed within six months post-closing.
Concurrent Novation Agreement with Nanobiotix consenting to the deal.

item 1.01 item 1.02

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.7

LianBio terminated License, Development and Commercialization Agreement with Nanobiotix S.A..

Action: termination
Agreement: license
Counterparty: Nanobiotix S.A.

Exact text from the filing

Item 1.02 Termination of a Material Definitive Agreement. The disclosures regarding the Transactions set forth in Item 1.01 above are incorporated by reference into this Item 1.02.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

LianBio entered into Asset Purchase Agreement with Janssen Pharmaceutica NV valued at $25 million (effective 2023-12-22).

Action: entry
Agreement: asset purchase
Counterparty: Janssen Pharmaceutica NV
Value: $25 million
Effective: 2023-12-22

Exact text from the filing

On December 22, 2023 (the “Closing Date”), LianBio Development (HK) Limited (“LianBio Development”), a subsidiary of LianBio, Janssen Pharmaceutica NV (“Janssen”), a Johnson & Johnson company, and, as applicable, LianBio entered into an Asset Purchase Agreement (the “APA”).

View on SEC.gov

148 material agreements filed in the last 30 days. Browse all material agreements →

LianBio filing history →

Source: SEC EDGAR

accession 0001831283-23-000145

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.